Artelo Biosciences wins Japan patent allowance for ART27.13 commercial formulation
- Artelo Biosciences received a notice of allowance in Japan for patent claims covering the intended commercial formulation of ART27.13.
- Claims cover compositions of ART27.13 dispersed in polyethylene glycol, matching claims previously allowed in the US and Europe.
- Patent protection across these jurisdictions is expected to run through 2041, strengthening the program’s global IP position.
- ART27.13 is being evaluated in two Phase 2 studies, including CAReS in cancer-related anorexia and DREAM in glaucoma or ocular hypertension.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200852PRIMZONEFULLFEED9813196) on August 20, 2026, and is solely responsible for the information contained therein.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Trade now！
You may also like
Crypto prices
More
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now